Claritev Corporation
CTEV · New York Stock Exchange · USD
24,00USD
+1,29 (+5,68 %)Stand 9. Nov., 21:00
Nachbörslich24,000,00 (0,00 %)17:05 ET
Kennzahlen
- Eröffnung
- 25,94
- Vortag
- 22,71
- Tagesspanne
- 22,68 – 28,28
- 52 Wochen
- 11,50 – 61,22
- Volumen
- 731.547
- Ø Volumen
- 161.726
- Börsenwert
- 406,74 Mio. $
- KGV
- -1,5
- Gewinn je Aktie (TTM)
- -16,42
- Dividendenrendite
- 0,0 %
- Beta
- 0,8
- Nächste Zahlen
- 22. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 965,41 Mio. | 930,62 Mio. | 961,52 Mio. | 1,08 Mrd. | 1,12 Mrd. |
| Herstellungskosten | 698,84 Mio. | 239,4 Mio. | 235,47 Mio. | 204,1 Mio. | 175,29 Mio. |
| Bruttogewinn | 266,58 Mio. | 691,22 Mio. | 726,06 Mio. | 875,62 Mio. | 942,31 Mio. |
| Forschung und Entwicklung | 0 | 0 | 0 | 0 | 0 |
| Vertrieb und Verwaltung | 221,52 Mio. | 160,22 Mio. | 135,99 Mio. | 132,14 Mio. | 151,1 Mio. |
| Operatives Ergebnis | 45,06 Mio. | −1,39 Mrd. | 161,98 Mio. | −362,73 Mio. | 386,12 Mio. |
| EBITDA | 475,44 Mio. | −1,01 Mrd. | 651,93 Mio. | 158,32 Mio. | 814,99 Mio. |
| Nettogewinn | −284,28 Mio. | −1,65 Mrd. | −91,7 Mio. | −572,91 Mio. | 102,08 Mio. |
| Gewinn je Aktie (verwässert) | -17,30 | -101,92 | -5,69 | -35,87 | 6,40 |
Umsatz nach Segment
Produkte · FY 2025
- Network Solutions206,69 Mio. $100,00 %
Anteil · ggü. Vorjahr (FY –)
Bewertung
Letzte 12 Monate
- KGV
- -1,5
- Kurs-Umsatz-Verhältnis
- 0,4
- Kurs-Buchwert-Verhältnis
- -1,2
- PEG
- -0,1
- Bruttomarge
- 33,8 %
- Operative Marge
- 5,8 %
- Nettomarge
- −27,1 %
- Verschuldungsgrad
- -13,4
- EV/EBITDA
- 10,3
- Eigenkapitalrendite
- 104,2 %
- Kapitalrendite (ROIC)
- 1,0 %
- Free-Cashflow-Rendite
- −6,8 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 27,6 % | 74,3 % | 75,5 % | 81,1 % | 84,3 % |
| Operative Marge | 4,7 % | −149,4 % | 16,8 % | −33,6 % | 34,5 % |
| Nettomarge | −29,4 % | −176,9 % | −9,5 % | −53,1 % | 9,1 % |
| KGV | -2,5 | -0,3 | -5,1 | -0,8 | 4,6 |
| Kurs-Umsatz-Verhältnis | 0,7 | 0,5 | 0,5 | 0,4 | 0,4 |
| Kurs-Buchwert-Verhältnis | -4,0 | 5,6 | 0,3 | 0,3 | 0,2 |
| Verschuldungsgrad | -26,6 | 54,0 | 2,7 | 2,7 | 2,1 |
| Liquidität 3. Grades | 0,9 | 0,8 | 1,2 | 2,5 | 2,2 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 5,32 Mrd. | 5 Mrd. | 4,97 Mrd. | 4,91 Mrd. | 5,22 Mrd. |
| EV/EBITDA | 11,2 | -5,0 | 7,6 | 31,0 | 6,4 |
| Eigenkapitalrendite | 163,5 % | −1.958,8 % | −5,4 % | −32,0 % | 4,4 % |
| Kapitalrendite (ROIC) | 0,7 % | −26,1 % | 2,0 % | −5,0 % | 3,6 % |
| Free-Cashflow-Rendite | −1,7 % | −2,2 % | 13,3 % | 60,6 % | 67,4 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +3,7 % | −3,2 % | −10,9 % | −3,4 % | +19,2 % |
| Bruttogewinn | −61,4 % | −4,8 % | −17,1 % | −7,1 % | +52,2 % |
| Operatives Ergebnis | +103,2 % | −958,1 % | +144,7 % | −193,9 % | +392,9 % |
| Nettogewinn | +82,7 % | −1.694,9 % | +84,0 % | −661,2 % | +119,6 % |
| Gewinn je Aktie | +83,0 % | −1.691,2 % | +84,1 % | −660,5 % | +114,5 % |
| Freier Cashflow | −16,8 % | −116,7 % | −77,8 % | −11,7 % | +4,4 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 5Kaufen
- 1Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
52,00
Durchschnitt · +116,67 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 1,01 Mrd. | 1,06 Mrd. | 1,11 Mrd. |
| Umsatz (Tief – Hoch) | 1 Mrd. – 1,02 Mrd. | 1,05 Mrd. – 1,07 Mrd. | 1,09 Mrd. – 1,13 Mrd. |
| Gewinn je Aktie (Ø) | -15,12 | -13,53 | -11,83 |
| Gewinn je Aktie (Tief – Hoch) | -15,27 – -14,92 | -13,66 – -13,35 | -11,92 – -11,65 |
| Analysten | 1 | 1 | 3 |
Letzte Änderungen
- Barclays21. Aug. 2026Overweight
- Wells Fargo12. Aug. 2026Equal Weight
- Citigroup10. Aug. 2026Buy
- Canaccord Genuity10. Aug. 2026Buy
- Canaccord Genuity21. Juli 2026Buy
- Wells Fargo19. März 2026Equal Weight
- Citigroup25. Feb. 2026Buy
- Wells Fargo24. Feb. 2026Equal Weight
Quartalszahlen
Nächste Zahlen: 22. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -3,63 | -4,12 | -3,81 | 0,85 | -3,12 | -2,69 | -2,20 | -9,81 |
| Gewinn je Aktie · Tatsächlich | -3,64 | -3,49 | -4,41 | -4,88 | -4,23 | -3,81 | -4,38 | -8,82 |
| Abweichung | −0,28 % | +15,29 % | −15,75 % | −674,12 % | −35,58 % | −41,64 % | −99,09 % | +10,09 % |
| Umsatz · Tatsächlich | 268,31 Mio. | 257,48 Mio. | 244,68 Mio. | 246,55 Mio. | 245,96 Mio. | 241,57 Mio. | 231,33 Mio. | 232,1 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 23. Sept. 20241:40
- 13. Juli 20158:1
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 83,08 %
- Investoren mit 13F-Meldung
- 113
Größte Investoren
- H&F CORPORATE INVESTORS VIII, LTD.22,92 %3,89 Mio.
- ARES MANAGEMENT LLC10,98 %1,86 Mio.
- ARINI CAPITAL MANAGEMENT LTD9,05 %1,53 Mio.
- PUBLIC INVESTMENT FUND7,55 %1,28 Mio.
- BEACH POINT CAPITAL MANAGEMENT LP4,54 %770.612
- BLACKROCK, INC.4,26 %723.217
- CPV PARTNERS, LLC2,92 %495.258
- VANGUARD CAPITAL MANAGEMENT LLC2,49 %423.039
Insider-Geschäfte
- ARES MANAGEMENT LLC26. Okt. 2026 · 10 percent ownerKauf20.834 Aktien · 24,07
- ARES MANAGEMENT LLC26. Okt. 2026 · 10 percent ownerKauf20.834 Aktien · 24,07
- ARES MANAGEMENT LLC23. Okt. 2026 · 10 percent ownerKauf50.000 Aktien · 23,53
- ARES MANAGEMENT LLC23. Okt. 2026 · 10 percent ownerKauf50.000 Aktien · 23,53
- Main Jennifer Elizabeth15. Okt. 2026 · directorKauf3113 Aktien
- Main Jennifer Elizabeth15. Okt. 2026 · director: Verkauf0 Aktien
- Misencik Tiffani15. Okt. 2026 · officer: SVP, Chief Growth OfficerVerkauf5812 Aktien · 23,81
- Misencik Tiffani14. Okt. 2026 · officer: SVP, Chief Growth OfficerVerkauf9994 Aktien · 23,94
Vergleichbare Unternehmen
Über das Unternehmen
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
Führung
- Travis S. DaltonChief Executive Officer, President & Chairman
- Douglas GarisExecutive Vice President & Chief Financial Officer
- Jerome W. HoggeExecutive Vice President & Chief Operating Officer
- Michael C. KimExecutive Vice President & Chief Digital Officer
- Tiffani D. MisencikSenior Vice President & Chief Growth Officer
- Carol H. NutterSenior Vice President & Chief People Officer
- CEO
- Travis S. Dalton
- Mitarbeitende
- 3.000
- Hauptsitz
- McLean, VA, US
- Sektor
- Healthcare
- Branche
- Medical - Healthcare Information Services
- Börsengang
- 3. Apr. 2020
- Website
- claritev.com
Nachrichten
- Seeking Alpha · 9. Nov., 14:01Claritev Corporation (CTEV) Q3 2026 Earnings Call Transcript
- MarketBeat · 9. Nov., 10:15What Claritev (CTEV) Said on Its Q3 Earnings Call
- Zacks Investment Research · 9. Nov., 8:21Claritev Corporation (CTEV) Reports Q3 Loss, Tops Revenue Estimates
- GlobeNewsWire · 9. Nov., 6:00Claritev Corporation Reports Third Quarter 2026 Results
- GlobeNewsWire · 5. Nov., 8:23Claritev Corporation Announces Participation in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- GlobeNewsWire · 29. Okt., 10:30Claritev Introduces Transparency-Based Pricing, Turning Complex Public Market Data into Actionable Reimbursement Intelligence
- Zacks Investment Research · 28. Okt., 10:25Claritev Corporation (CTEV) Surges 5.2%: Is This an Indication of Further Gains?
- Defense World · 19. Okt., 4:22Claritev (NYSE:CTEV) SVP Sells $138,383.72 in Stock
- GlobeNewsWire · 15. Okt., 9:00Claritev Appoints Jennifer Main to its Board of Directors
- GlobeNewsWire · 14. Okt., 8:00Claritev Corporation Announces Third Quarter 2026 Earnings Conference Call
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.